Abvc Biopharma price to sales ratio ABVC

Market value divided by revenue over the last twelve months, since 2020.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 88.9×; Aug 2025
6-year median: 113×
6-year range: 11.1× to 200×
Peer median: 0.4×

Abvc Biopharma's price to sales ratio is not a meaningful number today: revenue for one or more of the four quarters through 2026-06-30 is missing, so twelve months can't be added up.

It was last meaningful in Aug 2025, at 88.9×.

On the days it had one over the last 6 years, its median was 113×, from 11.1× in Feb 2025 to 200× in Dec 2020.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2025	88.9×	11.1×	131×
2024	14.8×	12.7×	98.4×
2023	n/m a value too high to mean anything
2022	150×	142×	180×
2021	184×	105×	200×
2020	200×	80.5×	200×

Against its peers

Companies in Drug Manufacturers - General nearest Abvc Biopharma's size, closest first, today.

Company	Price to sales ratio
ABVCAbvc Biopharma	n/m
ATNMActinium Pharmaceuticals	n/m
SPROSpero Therapeutics	1.4×
LFVNLifevantage	0.4×
NATRNatures Sunshine Products	0.4×
Peer median	0.4×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Abvc Biopharma

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.